Constant technological advancements for diagnosis and treating of hemophilia and high global prevalence of the disease are key factors driving market revenue growth.
Market Size - USD 12.41 Billion in 2020, Market Growth - CAGR of 5.2%, Market Trends - Constant research to explore and develop advanced drugs to treat hemophilia by major players along with government support.
The global hemophilia market size is expected to reach USD 18.75 Billion in 2028, and register a CAGR of 5.2% during the forecast period. Major factors driving market growth include increasing investments in research and development in the biotechnology field for hemophilia treatment, and increasing number of campaigns and government initiatives for spreading awareness about hemophilia condition and available drugs.
Hemophilia is a hereditary-genetic disorder, which refers to lower level or complete lack of proteins in an individual known as clotting factors. This condition impairs body’s ability to coagulate blood, leading to excessive bleeding. Types of Hemophilia include Hemophilia A and Hemophilia B, which have similar symptoms; however, are caused by mutations in different genes. As per reports in 2018, Hemophilia is among the rare hereditary diseases, known to have affect nearly 440,000 individuals globally.
Some Key Findings From the Report:
For the purpose of this report, the global hemophilia market is segmented on the basis of type, product, treatment type, therapy type, and region:
Type Outlook
Product Outlook
Treatment Type Outlook
Therapy Type Outlook
Region Outlook
Reasons to Buy the Report
Market Size - USD 12.41 Billion in 2020, Market Growth - CAGR of 5.2%, Market Trends - Constant research to explore and develop advanced drugs to treat hemophilia by major players along with government support.
The global hemophilia market size is expected to reach USD 18.75 Billion in 2028, and register a CAGR of 5.2% during the forecast period. Major factors driving market growth include increasing investments in research and development in the biotechnology field for hemophilia treatment, and increasing number of campaigns and government initiatives for spreading awareness about hemophilia condition and available drugs.
Hemophilia is a hereditary-genetic disorder, which refers to lower level or complete lack of proteins in an individual known as clotting factors. This condition impairs body’s ability to coagulate blood, leading to excessive bleeding. Types of Hemophilia include Hemophilia A and Hemophilia B, which have similar symptoms; however, are caused by mutations in different genes. As per reports in 2018, Hemophilia is among the rare hereditary diseases, known to have affect nearly 440,000 individuals globally.
Some Key Findings From the Report:
- Among the type segments, the hemophilia A segment accounted for the largest revenue share of 79.5% in 2020.
- North America market dominated in the global market over the forecast period, due to presence of major players in the countries in the region and high adoption of advanced treatment option among patients.
- The Asia Pacific market was valued at USD 2,482.6 Million in 2020, and is expected to register a robust revenue growth rate during the forecast period.
- Key players profiled in the report include Shire (Takeda), Bayer AG, CSL Behring, Novo Nordisk A/S, BioMarin Pharmaceutical Inc., Octapharma AG, Sanofi SA, Pfizer Inc., Biogen Inc., F. Hoffmann-La Roche AG, and Grifols International SA. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.
- In 2020, Novo Nordisk launched ESPEROCT - a long acting recombinant factor VIII product for prevention and treatment of bleeding in patients with hemophilia A.
- In 2019, F. Hoffmann-La Roche AG launched Emicizumab (Hemlibra) for Hemophilia A with the factor VIII inhibitors, which was approved specifically for use in India.
For the purpose of this report, the global hemophilia market is segmented on the basis of type, product, treatment type, therapy type, and region:
Type Outlook
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Product Outlook
- Plasma derived coagulation factor concentrates
- Factor VIII
- Factor IX
- Factor XII
- Activated prothrombin complex concentrate
- Von Willebrand factor
- Recombinant coagulation factor concentrates
- Factor VIII
- Factor IX
- Von Willebrand factor
- Desmopressin
- Antifibrinolytic agents
- Others
Treatment Type Outlook
- Prophylactic
- On-Demand
Therapy Type Outlook
- Replacement Therapy
- Immune Tolerance Induction Therapy
- Gene Therapy
Region Outlook
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
Reasons to Buy the Report
- A robust analysis and estimation of the Hemophilia Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
- A holistic competitive landscape of the all the major players in the Hemophilia Market. The report covers their market shares, strategic initiatives, new product launches, R&D expenditure, M&As, Joint ventures, expansionary plans, product wise metric space analysis and key developments
- Go-to-market strategies specifically formulated in line with location analysis which takes into the factors such as government regulations, supplier mapping, supply chain obstacles, and feedback from local vendors
- Most deep dive segmental bifurcation available currently in the market. Our stellar methodology helps us understand the overall gamut of the supply chain and will help you explain the current market dynamics
- Special focus given on vendor landscape, supplier portfolio, customer mapping, production capacity, and yearly capacity utilization
Table of Contents
Chapter 1. Market Synopsis
Chapter 2. Executive Summary
Chapter 3. Indicative Metrics
Chapter 4. Hemophilia Segmentation & Impact Analysis
Chapter 5. Hemophilia Market By Type Insights & Trends
Chapter 6. Hemophilia Market By Product Type Insights & Trends
Chapter 7. Hemophilia Market By Treatment Type Insights & Trends
Chapter 8. Hemophilia Market By Therapy Insights & Trends
Chapter 9. Hemophilia Market Regional Outlook
Chapter 10. Competitive Landscape
Chapter 11. Company Profiles
Companies Mentioned
- Shire (Takeda)
- Bayer Healthcare
- CSL Behring
- Novo Nordisk
- BioMarin
- Octapharma
- Sanofi
- Pfizer Inc.
- Biogen
- Roche
- Grifols International,
